To evaluate whether the presence of CTCs before and after therapy is linked to the course of disease, receiver operator characteristics (ROC) analysis was performed to identify a cut-off value for numbers of cytokeratin+ CD45− CTCs that discriminates between patients with and without recurrent cancers. This evidence concerns the gene PTPRC and cancer.